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Methamphetamine (MA) abuse is a global health concern due to widespread 
use and harmful effects, which includes neurotoxicity. This study aimed to 
describe neurocognitive deficits associated with MA dependence in young 
adults and to explore whether these deficits correlate with white matter (WM) 
microstructural abnormalities using diffusion tensor imaging (DTI).  
Methods 
Twenty-one MA dependent individuals recently enrolled in an outpatient 
rehabilitation program and nineteen healthy controls participated in the study. 
Each participant completed a neuropsychological evaluation and underwent 
diffusion tensor imaging within one week of testing. Average whole-brain 
fractional anisotropy (FA) and mean diffusion (MD) measures derived from 
DTI data were compared between groups. Group differences in performance 
within specific neurocognitive domains and in a composite global 
neurocognitive score (GNS) were tested using non-parametric univariate 
statistics and within a linear regression framework, adjusting for age and 
gender. Correlation analyses were conducted to test associations between 
the neuropsychological data and selected frontal white matter (WM) tracts, 
including the genu and body of the corpus callosum (CC); right and left 
cingulum bundle (CB); right and left uncinate fasciculus (UF); right and left 
anterior corona radiata (CR) and the right and left superior longitudinal 
fasciculus (SLF). 
Results 
No significant between-group differences were detected for performance in 
any of the neuropsychological domains assessed. No relationship between 
FA or MD and the GNS was demonstrated in the tracts of interest. After 
adjusting for age and gender, significant group differences in FA and MD were 
detected across several regions of interest (ROI), however, these did not 
survive corrections for multiple comparisons.  
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Conclusion 
Cognitive performance and white matter integrity did not differ between young 
MA dependent subjects and healthy controls. Whatever differences that were 
found in white matter did not survive correction for multiple comparisons. 
These findings may reflect one or more of several possibilities: that brain 
function and structure is relatively preserved in younger individuals; or that 
differences were too small to be detected in this sample. Further studies 
should explore the effects of aging, poly-substance abuse and HIV co-
infection on neurocognitive functioning and structural brain integrity in 
methamphetamine users. 
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CHAPTER 1: INTRODUCTION 
1.1 Context 
1.1.1 Methamphetamine use in South Africa 
Methamphetamine (MA), like cocaine, is a powerful stimulant drug of abuse 
with widespread illegal use. It’s popularity peaked in the United States (US) in 
the 1960s and later in the 1990s, with production largely driven by small-scale 
informal laboratories making use of readily available ingredients, e.g. pseudo 
ephedrine in cold and flu medication (Ciccarone 2011). MA abuse is 
traditionally associated with certain subgroups (e.g. gang members; sex 
workers; truck drivers; gay men), although growing concern has been 
expressed over its escalating use in South Africa (SA), particularly the 
Western Cape population (Brecht et al. 2004; Pluddemann et al. 2010). 
Despite numerous negative consequences affecting social, physical, 
psychological and occupational well-being, South Africans continue to abuse 
MA. Furthermore, in the context of South Africa’s high HIV prevalence, the 
associated risk of HIV exposure, increased transmission rates, treatment non-
adherence and disease progression in individuals who abuse MA is of grave 
concern (Kapp 2009; Colfax et al. 2010; Carrico et al. 2011). This chapter will 
outline some of the known deleterious effects of MA on human brain structure 
and function and will further describe the ethical considerations necessary for 
research in this study population. 
1.1.2 Methamphetamine and neurotoxicity 
MA is a highly lipophilic, neurotoxic molecule capable of producing significant 
disruption in brain structure and function. Animal and human studies support a 
dose-related association between acute and chronic MA use and 
neurotoxicity. Rats exposed to MA exhibit decreased levels of striatal 
dopamine as well as destruction of dopaminergic nerve terminals (Ricaurte et 
al. 1982). Serotonergic function is also compromised following MA exposure 
as evidenced by: loss of the 5-HT transporter; 5-HT depletion; depletion of 5-
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HT metabolites and reductions in tryptophan hydroxylase (as reviewed in 
Meredith et al 2005) (Meredith et al. 2005). Post mortem findings further 
support alterations in dopaminergic functioning seen in neuroimaging studies 
as evidenced by deficits in available dopamine, the dopamine transporter and 
tyrosine hydroxylase, a dopamine precursor (Wilson et al. 1996). 
Proposed mechanisms of neurotoxicity include accumulation of reactive 
oxygen species and severe oxidative stress, glutamate mediated excitotoxicity 
and mitochondrial dysfunction, preferentially affecting striatal dopaminergic 
nerve terminals (Quinton & Yamamoto 2006). Davidson et al. further postulate 
that MA induced neurotoxicity occurs via two pathways i.e. loss of 
dopaminergic function in acute overdose (4 x 5mg/kg) and MA induced 
apoptosis seen in chronic use (15mg/kg/day x 14 days) (Davidson et al. 
2001).  
1.1.3 Methamphetamine and cognition 
Long-term/chronic MA use has been shown to result in significant cognitive 
impairment affecting multiple domains. Up to 40% of long-term MA dependent 
individuals exhibit global neuropsychological impairment (Rippeth et al. 2004). 
Cognitive processes dependent on frontal-striatal and limbic circuits are 
predominantly affected in MA abuse, irrespective of age and level of 
education (Scott et al. 2007). The following domains have been shown to be 
impaired: episodic memory; prospective memory; executive function, complex 
information processing speed and psychomotor function (Scott et al. 2007; 
Rendell et al. 2008). Smaller effect sizes were noted in attention/working 
memory, language and visual construction. Successful rehabilitation, including 
therapeutic strategies, abstinence and impulse control, rely heavily on the 
aforementioned neuropsychological domains being intact. Impairment in 
areas such as learning, memory and impulse control may help to explain the 
difficulty experienced by MA users, engaged in a rehabilitation program, to 
refrain from using the drug (Gowin et al. 2013). 
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Despite increasing numbers of individuals using MA, few studies of this nature 
exist in South African populations. This research may further enhance our 
understanding of the complex maladaptive behaviours seen in substance-
dependent individuals.  
1.1.4 Methamphetamine and diffusion tensor imaging 
Magnetic resonance imaging (MRI) plays an increasingly important role in 
understanding brain structure and function in both normal and diseased 
states. Diffusion tensor imaging (DTI) was introduced in 1994 and is one of 
several MRI modalities that allow for the non-invasive study of white matter 
integrity based on the free diffusion of water molecules within white matter 
tracts (Assaf & Pasternak 2007; Le Bihan et al. 2001). As reviewed in Salo 
and Fassbender, a rich body of literature of animal studies exists supporting 
the deleterious effects of MA on brain white matter, however, few human 
studies have been published (Tabled below) (Salo & Fassbender 2011). 
Furthermore, the combination of DTI parameters correlated with cognitive 
measures could provide a useful marker of human behaviour and response, 
for example, predicting treatment outcomes in a rehabilitation setting. 
DTI employs the principle of Brownian motion i.e. the random movement of 
water molecules within a space. This motion is deemed isotropic if movement 
occurs equally in all directions. If water molecules are restricted in a plane e.g. 
along the axis of a neuron, movement will occur at different speeds with those 
along the axon moving the fastest compared to molecules moving 
perpendicular to the axis. This property of molecules in motion is called 
anisotropy and, with the aid of sophisticated MRI techniques, can be used to 
demonstrate the direction of water molecules along white matter tracts. These 
in turn allow clinicians to visualize anisotropic diffusion of water molecules 
within several cubic mm of white matter, known as a voxel, which may be 
representative of several disease states (Le Bihan et al. 2001). The resultant 
anisotropy allows for information to be gained on both tissue microstructure 
and architecture within the voxel. DTI has been successfully employed to 
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demonstrate disruption of brain tissue in a number of pathological states. 
Examples include: demyelination in multiple sclerosis and oedema in 
response to inflammation seen in acute cerebrovascular accidents (CVA) 
(Filippi et al. 2001; Sotak 2002). 
Fractional anisotropy (FA) is the most frequently used parameter of DTI. FA 
provides information on the orientation and integrity of white matter fibers 
within a voxel. Each voxel consists of thousands of white matter fibers and a 
supportive matrix of glial cells, including oligodendrocytes responsible for the 
myelin sheath around the axon. FA comprises of an intensity scale that 
ranges between zero and one. FA is high (close to one) if diffusivity is rapid 
along fibres and approaches zero if diffusion occurs in all directions (Assaf & 
Pasternak 2007).  Mean diffusivity (MD) provides an overall measure of 
diffusivity within a voxel or region. MD is understood to increase in 
pathological disease states e.g. inflammation and oedema (Le Bihan et al. 
2001). FA is thought to decrease in the presences of tissue damage, due to 
either increased radial (RD) or decreased axial diffusivity (AD). More recently, 
imaging specialists have started to examine AD and RD as separate entities, 
in combination with FA, in order to glean more information on tissue structure 
(Alexander et al. 2007). Several limitations should be taken into consideration 
when interpreting data obtained using DTI. These include: artifact; thermal 
and physiological image noise; dilution of volume when averaged in larger 
voxels and fibre crossing (Alexander et al. 2007). 
1.1.5 Literature review of DTI studies in methamphetamine dependence 
A literature review conducted, using Pubmed Central, of DTI studies 
undertaken in MA dependence yielded the results summarized in Table X 
below. Keywords used in the search include: ‘DTI’, ‘diffusion tensor imaging’ 
‘methamphetamine’, ‘MA’, ‘amphetamine’ and ‘structural imaging’	
(Alicata et al. 2009; Chung et al. 2007; Ersche et al. 2012; Kim et al. 2009; 
Salo et al. 2009; Tobias et al. 2010; Lederer et al. 2015). 
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Table I: Literature review of DTI studies in MA dependence 
Primary 
author 
Year Sample Whole brain voxel 
analysis or ROI 
Measure Significant findings 
Alicata 2009 30 MA +, 30 
MA -; age 
33.3 (8.6) 
Frontal WM; parietal 




FA, ADC MA +: decreased FA in right 
frontal WM; increased ADC in 
left caudate and bilateral 
putamen. 
Higher ADC in left putamen 
and higher right putamen was 
associated with higher MA 
doses. 





age men 36.0 
(6.7), women 
29.0 (7.2) 
Bilateral frontal WM; 
bilateral parietal WM; 
bilateral occipital WM. 
(frontal matter 
measured relative to 
the AC-PC plane 
FA MA +: Decreased FA in 
bilateral frontal WM at the AC-
PC plane and right frontal WM 
above this plane. Less 
prominent in female 
participants.  
Ersche 2012 50 sibling 
pairs with at 




Tract-based skeleton FA Decreased mean FA in MA + 
and their siblings compared to 
healthy controls. Therefore 
observed WM abnormalities 
were shared among family 
members and may have pre-
disposed them to drug-taking. 




(Not tested for 
HIV); age 34.4 
(2.9) 
Genu and splenium of 
the CC 
FA Decreased FA in genu; trend 
to decreased FA in splenium 
although not significant. 
Lederer 2016 40 MA +, 40 
matched 
controls 








Increased MD and increased 
perpendicular diffusivity in the 
genu of the corpus callosum. 
Increased MD in the right 
cingulum. None of the WM 
changes were significantly 
associated with aggression. 
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Salo 2009 37 MA +, 17 
healthy 
controls 
Genu and splenium of 
the CC 
FA, ADC No significant difference in FA 
and ADC across groups. 
Trend towards decreased FA 
in genu but not significant 
(p=0.9) 






















FA Lower FA: Right prefrontal WM 
above the AC-PC; midline 
genu CC; left and right 
midcaudal superior corona 
radiate and right perforant 
fibres. 
WM = White matter; AC-PC = Anterior commissure-posterior commissure 
CR = Corona radiata 
Few studies appear to have been conducted in this area despite many 
authors emphasizing the value of DTI in understanding microstructural 
abnormalities associated with MA addiction. Replication of these studies in a 
South African, MA dependent population, correlating neuropsychological 
deficits with white matter deficits seen on DTI, will be of great value and may 
provide further insight into understanding maladaptive behavioural patterns 
associated with MA abuse.  
1.2 Ethical considerations 
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Good clinical practice principles ensure that research conducted in clinical 
populations adheres to sound ethical and scientific standards, at all times, in 
order to protect the rights, safety and well being of study participants. Several 
special considerations need to occur when research is conducted with human 
subjects who abuse substances. Firstly, ethical approval of the study protocol, 
in accordance with the principles laid down by the Declaration of Helsinki, 
must occur prior to the commencement of research. This research study was 
approved by the Human Research Ethics Committee (HREC) of the University 
of Cape Town on the 6th of July 2010 (HREC 263/2010), initially as part of a 
larger parent study, i.e. Methamphetamine induced deficits in neuro-and-
social cognition in the context of HIV infection (Appendix A), and later as a 
separate protocol for the achievement of a Masters of Philosophy (MPhil) in 
Neuropsychiatry on the 29th of August 2014 [HREC 635/2014] (Appendix B). 
For the purpose of fulfillment of the MPhil requirements, this thesis focused 
exclusively on HIV negative, methamphetamine dependent individuals and 
HIV negative, healthy controls. Permission was obtained from both the City of 
Cape Town and the Provincial Government of the Western Cape to conduct 
research in the relevant treatment facilities (Appendix E). 
According to the Belmont Report, the following ethical principles should guide 
all clinical research: respect for persons; beneficence and justice. I will 
address each principle individually with regards to this research study. 
(i) Respect for persons: every participant was comprehensively informed of
the study prior to enrollment. I presented an information session to both staff
and incumbents at Matrix clinic on the known effects of MA on the brain to
ensure adequate knowledge on the purpose of the research (Appendix C).
Participation was voluntary and all subjects were informed that they were able
to withdraw from the study at any point without negative consequences. All
participants were actively enrolled in their rehabilitation programme and had
full capacity, thus ensuring competence to sign informed consent. Acutely
intoxicated participants were not considered for the study. The investigators
covered all transport costs and participants were compensated with food
vouchers for the two days spent engaged in study procedure. Participants
were not compensated with cash at any point due to the risk of this being
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used to purchase illicit drugs. Participants were free of undue influence and 
not coerced to participate in the study. (ii) Beneficence: the investigators 
maintained ongoing awareness of minimizing risk for participants while 
maximizing potential benefit without permanent injury at all times. Due to the 
cross-sectional nature of the study, potential risks mostly pertained to 
procedure on the study day. Study participants were informed of all study 
procedures i.e. neuromedical exam; neuropsychological testing and MRI, with 
their comfort and safety prioritized at all times. (iii) Justice: selection of study 
participants ensured fair distribution of the risks and benefits of the research. 
Members of the healthy control group comprised of family and friends of the 
MA dependent group and were invested in advancing scientific knowledge of 
MA abuse despite not being addicts themselves. 
In addition to the above considerations, the counselors at Matrix were 
informed of those participating in this research study. With the participants 
consent, essential clinical information was shared with the counselor to 
ensure adequate support for the participant throughout the study process. 
1.3 Author Guidelines for PSYCHIATRY RESEARCH: NEUROIMAGING 
The journal Psychiatry Research is the official publication of The International 
Society for Neuroimaging in Psychiatry. The Neuroimaging section caters for 
a variety of publications related to brain imaging of psychiatric disorders 
including: structural imaging; effects of behavioural tasks and impact of 
medication within this realm. The journal carries an impact factor of 2.831 (© 
Thomas Reuters Journal Citation Reports 2014). 
The selection of this journal is an appropriate platform for my study as it 
encompasses brain imaging of a known noxious agent to the brain 
(methamphetamine) and correlates these findings with cognitive deficits 
present in this study population. These cognitive deficits in turn are associated 
with certain deleterious behaviours e.g. executive dysfunction resulting in poor 
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planning and execution of rehabilitation endeavours. The findings of such a 
study may help to link structural imaging with associated human behaviours, 
furthering our scientific understanding of addiction and subsequent treatment 
planning. This journal is listed on the Thomas Reuters/Institute for Scientific 
Information (ISI) Web of Science list January 2014: ISSN 0925-4927; E-ISSN 
1872-7506; Netherlands. 
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CHAPTER 2: PUBLICATION-READY MANUSCRIPT 
WHITE MATTER CORRELATES OF NEUROPSYCHOLOGICAL 
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Abstract 
Background 
Methamphetamine (MA) abuse is a global health concern due to widespread 
use and harmful effects, which includes neurotoxicity. This study aimed to 
describe neurocognitive deficits associated with MA dependence in young 
adults and to explore whether these deficits correlate with white matter (WM) 
microstructural abnormalities using diffusion tensor imaging (DTI).  
Methods 
Twenty-one MA dependent individuals recently enrolled in an outpatient 
rehabilitation program and nineteen healthy controls participated in the study. 
Each participant completed a neuropsychological evaluation and underwent 
diffusion tensor imaging within one week of testing. Average whole-brain 
fractional anisotropy (FA) and mean diffusion (MD) measures derived from 
DTI data were compared between groups. Group differences in performance 
within specific neurocognitive domains and in a composite global 
neurocognitive score (GNS) were tested using non-parametric univariate 
statistics and within a linear regression framework, adjusting for age and 
gender. Correlation analyses were conducted to test associations between 
the neuropsychological data and selected frontal white matter (WM) tracts, 
including the genu and body of the corpus callosum (CC); right and left 
cingulum bundle (CB); right and left uncinate fasciculus (UF); right and left 
anterior corona radiata (CR) and the right and left superior longitudinal 
fasciculus (SLF). 
Results 
No significant between-group differences were detected for performance in 
any of the neuropsychological domains assessed. No relationship between 
FA or MD and the GNS was demonstrated in the tracts of interest. After 
adjusting for age and gender, significant group differences in FA and MD were 
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detected across several regions of interest (ROI), however, these did not 
survive corrections for multiple comparisons.  
 
Conclusion 
Cognitive performance and white matter integrity did not differ between young 
MA dependent subjects and healthy controls. Whatever differences were 
found in white matter did not survive correction for multiple comparisons. 
These findings may reflect one or more of several possibilities: that brain 
function and structure is relatively preserved in younger individuals; or that 
differences were too small to be detected in this sample. Further studies 
should explore the effects of aging, poly-substance abuse and HIV co-





Methamphetamine (MA) is stimulant drug of abuse known to have detrimental 
effects on brain structure and function (Courtney & Ray 2014). MA presents a 
global health concern due to its addictive nature, widespread use and 
neurotoxic properties. Informal methamphetamine labs/kitchens are able to 
produce cheaper, more potent MA and continue to drive this problem 
(Maxwell & Brecht 2011; Brecht et al. 2004). South Africa, particularly the 
Western Cape province, is facing a growing MA epidemic (Plüddemann et al. 
2013). According to the South African Community Epidemiology Network on 
Drug Use (SACENDU), 35% of individuals seeking treatment for drug use in 
2006 report MA as their primary drug of choice (Pluddemann et al. 2008). 
 
This highly lipophilic molecule dramatically enhances the release of 
catecholamines (dopamine; noradrenaline and serotonin) in the central 
nervous system and partially blocks their re-uptake. The increase in available 
catecholamines further stimulates the corresponding postsynaptic receptors 
(Cruickshank & Dyer 2009). Disruption of these neurotransmitter systems is 
thought to underlie the predominantly frontostriatal pattern of neurocognitive 
dysfunction previously reported in MA dependent individuals (Sekine et al. 
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2003). Deficits in episodic memory; executive function; motor skills; 
information processing speed and language have all been described in acute 
and chronic MA use (Maxwell & Brecht 2011; Scott et al. 2007). Some of 
these data suggest that decision-making may be impaired in MA dependent 
individuals, leading to high-risk behaviours and poor treatment outcomes 
(Pluddemann et al. 2008; Paulus et al. 2002). Intact neurocognitive function is 
important to treatment planning (many of which are cognitively-based 
interventions) and long-term rehabilitation.  
This study aimed to investigate whether a young adult, MA dependent, South 
African population display neurocognitive deficits, and associated WM 
abnormalities detected on diffusion tensor imaging (DTI). DTI is a magnetic 
resonance imaging (MRI) modality, which allows for the non-invasive, in-vivo 
study of brain white matter (WM) structure based on the free diffusion of water 
molecules within WM tracts (Assaf & Pasternak 2007). The extent to which 
water molecules move within the same orientation within white matter fiber 
tracts, known as anisotropic diffusion, can be used to infer tissue 
microstructural abnormalities in certain disease states i.e. demyelination; 
inflammation; oedema; neoplasia and stroke (Alexander et al. 2007; Le Bihan 
et al. 2001).  
Fractional anisotropy (FA) is a parameter of DTI and provides information 
about the orientation of white matter fibers within a voxel. FA is high (close to 
1) if diffusivity is rapid and uninterrupted along fibers whereas FA approaches
zero if diffusion occurs in all directions (Assaf & Pasternak 2007). Mean
diffusivity (MD) provides an overall measure of diffusivity within a voxel or
region and is understood to increase in pathological disease states (Le Bihan
et al. 2001). For instance, in the MA DTI literature, Chung and colleagues
demonstrated disruption of frontal structures in abstinent MA users in the
anterior-posterior commissure (AC-PC) plane, which correlated with an
impaired performance on the Wisconsin Card Sorting Test (WCST), a
measure of executive functioning (Chung et al. 2007). Their group reported
that male MA dependent subjects had significantly lower FA values in frontal
white matter, compared to female MA participants and more errors on the
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WCST. Kim et al. (2009) further demonstrated abnormal WM in the genu of 
the corpus callosum (CC) with corresponding impairment on the WCST. 
Lederer and colleagues demonstrated increased MD in the genu of the CC 
and right cingulum in chronic MA users (Lederer et al. 2015). DTI, combined 
with cognitive measures, could potentially provide a useful marker of MA 
induced alterations in human behaviour and response, for example, predicting 
treatment outcomes in a rehabilitation setting. 
Our hypothesis was that WM abnormalities would follow a predominantly 
fronto-subcortical pattern in MA dependent individuals and would be 
associated with neurocognitive dysfunction represented by WM tracts in these 
areas. We predicted that group differences would be present in the following 
major frontal WM pathways: genu and body of the corpus callosum (CC) and 
right and left cingulum bundle (CB); right and left uncinate fasiculus (UF); the 
superior longitudinal fasciculus (SLF) and the anterior corona radiata (CR). 
The selection of the aforementioned WM tracts is based on the ICBM-DTI-81 
white-matter atlas and represents tracts previously reported on in a separate 
cohort of methamphetamine patients by our lab (Mori et al. 2008; Uhlmann et 
al. 2016). 
This study was approved by the University of Cape Town Human Research 
Ethics Committee (HREC no: 635/2014), and was conducted in accordance 
with the principles laid down by the Declaration of Helsinki 2013. 
2. Methods and materials
2.1. Subjects
All MA dependent individuals, aged 18-40 years, attending the Tafelsig Matrix
Rehabilitation Centre in Cape Town, South Africa, during the period of
December 2011 to December 2012 were invited to participate in the study.
Healthy, non-using, control subjects of a similar age were recruited in a
convenience fashion from friends and family of MA + users living within the
same community. Inclusion criteria for MA + participants were as follows: (1)
completed 7 years of formal schooling; (2) right-handed; (3) able to converse
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in English or Afrikaans and (5) MA dependence, as confirmed by the Mini 
International Neuropsychiatric Interview (MINI-500)(Sheehan et al. 1997). 
 
Participants were excluded from the study if they were found to have the 
following: (1) a history of past or current serious mental illness (e.g. 
schizophrenia, bipolar mood disorder); (2) a history of past or current 
neurological illness affecting the brain (e.g. cerebrovascular illness, epilepsy); 
(3) severe systemic illness or significant head injury (loss of consciousness > 
30mins and/or requiring an admission to hospital); (4) past or current 
substance abuse other than MA; alcohol; cannabis or nicotine; (5) HIV 
seropositivity; (6) contraindication to MRI and (7) refusal to sign informed 
consent. MA+ participants were required to abstain from MA use for 3 days 
prior to the neuropsychological assessment and 7 days prior to the 
neuroimaging. This was confirmed on self-report and by means of a urine 
drug screen (UDS) for amphetamines; opiates; cannabis and 
benzodiazepines. The Drug Use Disorders Identification Test (DUDIT), a 
sensitive, 11-item self-report tool, was used to screen for any substance use, 
in addition to methamphetamine (A. H. Berman et al. 2005). Healthy controls 
were excluded for any substance use, including cannabis. The DUDIT was 
used in conjunction with the Alcohol Use Disorders Identification Test 
(AUDIT), a widely used, validated 10-item tool allowing investigators to screen 
for excessive alcohol use (Bohn et al. 1995). 
 
Measurement of total MA dose is notoriously difficult. In South Africa, MA is 
distributed in the form of straws at a cost of 40-60 ZAR per straw (the length 
of a drinking straw is filled with MA and divided into segments).  Ten straws 
are estimated to hold an equivalent of 1 gram of MA, although this 
measurement may be inaccurate as the MA is often combined with other 
substances, such as talcum powder. For this study participants were asked to 
report dose as either number of straws or grams used per day or both. All 
participants signed full informed consent prior to entry in the study. 
 
2.2. Neuropsychological assessment  
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The cognitive evaluation occurred on a single test day and was undertaken in 
the participant’s first language (English or Afrikaans). The neuropsychological 
(NP) test battery was selected by a trained local neuropsychologist (HG) with 
expertise in MA abuse. The domains chosen for this study represent those 
most frequently associated with deficits in MA abuse (Scott et al. 2007; 
Gonzalez et al. 2004), and include the following tests, as listed in Table 2: (1) 
motor speed (Grooved Pegboard Test); (2) episodic memory (Hopkins Verbal 
Learning Test –Revised; total and delayed); (3) attention/working memory 
(WAIS – III Digit Span Subtest); (4) speed of information processing (Color 
Trails; WAIS – III Digit Symbol Subtest; Stroop color/word); (5) verbal fluency 
(Letter Fluency; Category Fluency) and (6) executive function (Stroop Color 
and Word; Color trails -II; Hayling Test). 
2.3. Diffusion tensor imaging acquisition and processing 
Magnetic resonance imaging was performed on a Siemens Magnetom 3T 
Allegra at the Cape Universities Brain Imaging Centre (CUBIC), within one 
week of the neuromedical and neuropsychological assessment. DTI data was 
acquired with the following parameters: TR=8800ms, TE=88ms, 30 diffusion-
weighted volumes with b=1000sec/mm2 and 3 unweighted volumes 
(b=0sec/mm2). In-plane resolution was 2×2 mm2 with a slice thickness of 2.2 
mm. The sequence was repeated 3 times to improve signal-to-noise ratio. In
order to facilitate registration of the DTI data in standard space, thereby
allowing group comparisons of DTI outcomes, a high resolution multi-echo
MPRAGE T1-weighted image was acquired, with the following parameters:
TR=2530ms; TE=1.64ms, 3.5ms, 5.36ms and 7.22ms; FOV=256x256; 176
slices, 1mm isotropic voxel size.
The 3 b=0sec/mm2 images for each DTI repetition were averaged to improve 
the signal-to-noise ratio. Eddy current correction was performed with the 
FMRIB Software Library (FSL 4.1.8) on each acquisition (Smith et al. 2006). 
Data were exported to Matlab (Mathworks Inc, Natick, MA) for further 
processing with all three acquisitions being co-registered by using the b=0 
mm/s2 as reference. The DTI acquisitions were averaged and exported to FSL 
for tensor fitting and brain extraction. Outliers were calculated by obtaining the 
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Z-value of the tensor estimates at the 25th and 75th percentile.  Outliers were
discarded if the data points were more than 3 standard deviations from the
mean. Whole brain statistical analysis was undertaken using FSL’s tract-
based spatial statistics (TBSS) software program (Smith et al. 2006). The
surface data produced by Freesurfer was smoothed and imported into
Freesurfer's qdec toolbox for vertex-level analysis. The following ROIs were
selected based on a predefined mask as per the ICBM-DTI-18 white matter-
labels atlas: genu and body of the corpus callosum (CC) and bilaterally for the
cingulum bundle (CB); the uncinate fasiculus (UF); the superior longitudinal
fasciculus (SLF) and the corona radiata (CR)(Mori et al. 2008).
2.4. Statistical analysis 
MA + users were compared with healthy controls with respect to demographic 
and clinical characteristics. The effect of gender on these sample 
characteristics was also determined. Group differences on categorical data 
were assessed using chi-square tests. Continuous outcomes were analysed 
using independent t-tests, or alternatively, non-parametric two-sided Mann 
Whitney or Kruskal-Wallis tests in cases in which parametric assumptions of 
normality and heteroscedascity were not confirmed. 
Neurocognitive domains scores were calculated by normalising the raw 
scores from constituent tasks by means of their conversion into Z scores, and 
then averaging the resulting scores across the tasks within each domain. The 
rationale behind creating Z scores is to have standardized scores on the 
same scale which can be compared across domains. Z scores were obtained  
by substracting the mean of the scores of the healthy control group from the 
mean of the MA + group and dividing the result by the standard deviation of 
the control group. i.e. XMA + - X MA- /SD	(MA-).	In addition, a global neurocognitive 
score (GNS) was derived from the mean Z score across all of the domains for 
each participant. Group differences in domain scores were determined using 
independent samples t-tests. In order to adjust for the effects of age and 
gender on domain scores, test estimates for between-group comparisons on 
the domain scores were also extracted from linear regression models with 
group membership, age and gender as predictor variables. In addition, non-
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parametric spearman’s correlations were calculated between the FA and MD 
measures from the tracts of interest and the GNS within each of the groups. 
The risk of false positives was minimised by employing bonferroni correction 
for multiple comparisons 
All statistical analyses were conducted using the R statistical computing 




21 MA abusers (48% male, mean age = 26.7 years) currently engaged in the
MATRIX rehabilitation program and 19 healthy controls (26% male, average
age = 27.4 years) participated in this research study. The study groups were
comparable with respect to age, education, housing and relationship status
(see Table 1). There was no difference in alcohol use between the two groups
as measured on the AUDIT (p>0.1). There was preliminary evidence that
concurrent cannabis use was greater in male MA subjects, though this was
not statistically significant (p=0.06).
3.2 MA use characteristics 
The average age of first MA use was 19.6 years of age. Most MA users 
engaged in daily use of the drug. Males and females did not differ with respect 
to age of first use of MA, duration of use or abstinence, amount of money 
spent on MA per week, and the frequency or estimated amount of MA used 
(see Table 1).  
3.3. Neuropsychological testing 
No statistically significant differences in neurocognitive performance were 
found between MA dependent individuals and healthy comparison subjects for 
any of the cognitive domains (Table 2).  
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3.4. Diffusion tensor imaging analysis 
3.4.1 Effect of MA on mean diffusion (MD) 
Regression models of group differences for the frontal tracts of particular 
interest in this study (genu and body of the CC, bilateral cingulum bundle; 
bilateral uncinate fasciculus; bilateral anterior corona radiata; bilateral superior 
longitudinal fasciculus) revealed a sub-threshold increase in MD in the right 
uncinate fasciculus (t = -1.79, p = 0.08), after adjusting for the effects of age 
and gender (Table 3). Age had a significant impact on several ROIs after 
adjusting for gender and MA use. These, however, did not survive bonferroni 
correction for multiple comparisons.  
Given lack of evidence of group differences in the planned comparisons, post-
hoc exploratory univariate comparisons of mean diffusion for forty-eight ROIs 
between the groups was conducted. These additional analyses detected 
significantly increased MD in the external capsule only (unadjusted p = 0.02) 
in MA participants (Table S2).  
3.4.2 Effect of MA on fractional anisotropy (FA) 
There was no evidence from regression models for group differences between 
the tracts of interest (Table 3). Sub-threshold evidence of a decrease of FA in 
the left superior longitudinal fasiculus relative to the control group was 
observed in MA+ patients, however (t = 1,96, p = 0,06). 
Additional post-hoc exploratory univariate DTI comparisons for the 48 ROIs 
revealed no significant differences in FA between MA dependent users and 
healthy controls (Table S1). Greater age was associated with a significant 
reduction in FA in the right uncinate fasiculus (p=0,04), after adjusting for 
gender and group status. 
3.4.3 Relationship between neuropsychological performance and DTI in 
selected ROIs 
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Greater FA in the left uncinate fasciculus was associated with an impaired 
global neurocognitive score in MA dependent individuals (Rho  = -0.48, p = 
0.04), but not in controls (Rho = 0.05, p = 0.85; see Table 4), a difference 
which did not survive correction for multiple comparisons. MD scores were not 
informative with respect to cognitive impairment for any of the ROIs.  
4. Discussion
In this pilot study of young adult, MA dependent users, we were not able to
demonstrate significant differences in neuropsychological performance or
white matter abnormalities on DTI when compared with healthy control
participants. No significant between-group findings for both FA and MD were
observed in our tracts of interest. After adjusting for age and gender, though,
a sub-threshold decreased FA was observed in the left superior longitudinal
fasiculus in MA+ patients, and increased MD in the right uncinate fasiculus.
The above findings were consistent with our hypothesis and in keeping with
reported DTI findings in the MA literature. In addition, increased FA in the left
uncinate fasciculus was associated with poorer neuropsychological
performance, as measured by a global neurocognitive score, however, none
of these findings survived correction for multiple comparisons.
A number of factors may have contributed to the negative findings of this 
study. The average age of our study sample (26.7 years) was considerably 
younger than populations reported in the MA / DTI literature. For instance, 
Salo and colleagues (2009) demonstrated WM abnormalities in the CC, 
correlating with poor cognitive control, in MA users with an average age of 
36.29 (±8.7) years. Kim et al. (2009) reported on MA dependent subjects with 
an average age of 34.4 (±2.9) years and showed decreased FA in the CC, 
which corresponded with a worse performance on the Wisconsin Card Sorting 
Test (WCST). Younger age may be protective in MA use, raising the 
possibility of an initial adaptive response to MA due to increased neuronal 
plasticity in younger brains, as suggested by Berman and colleagues (Berman 
et al. 2008). Furthermore, a temporary imbalance in the frontostriatal circuits 
due to differences in maturation rates between the cortex and striatum has 
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been suggested by Vink and colleagues (Vink et al. 2014). This may serve to 
explain some variability in the neuropsychological task performance. Our 
sample also had a relatively shorter duration of MA use in comparison to other 
study populations (7.4 ± 3.65 vs. 10.6 ± 2.7 years in Kim et al. (2009)), which 
may have impacted on the severity of neurotoxicity and subsequent WM 
damage. Furthermore, the effects of gender should be considered, particularly 
with regards to MA use characteristics. Although our sample was small and 
differences between male and female participants were not significant, male 
MA users engaged in more frequent MA use; had a longer duration of use and 
were more likely to abuse cannabis. A larger sample may reflect both DTI and 
neuropsychological differences associated with these differences. 
In keeping with Chung et al. we expected to find lower FA values in the 
prefrontal and frontal cortices (Chung et al. 2007). Microstructural WM 
abnormalities are present within 7-13 days of abstinence from MA, notably in 
the prefrontal cortex and hippocampal formation (Tobias et al. 2010). The 
duration of abstinence in our sample ranged from an average of 38.8 days 
(range: 10-65 days) in male subjects to 60 days (range: 24-126 days) in 
female MA users. The absence of WM abnormalities in this sample is 
unexpected and may indicate the possibility of neuronal recovery during the 
abstinent period. Nordahl et al. (2005) suggest a period of normalization of 
neuronal structure and function following MA abstinence, supported by the 
normalization of choline levels on magnetic resonance spectroscopy in the 
anterior cingulum. Wang et al demonstrated recovery of thalamic metabolism 
in abstinent MA users and suggest that this may reflect a compensatory 
response to the dopaminergic deficit present in the striatum, subsequently 
improving neuropsychological performance (Wang 2004). Furthermore 
Volkow et al. (2001) demonstrated the recovery of the dopamine transporter 
following protracted abstinence from MA. FA is a measure of the movement of 
water molecules within WM tracts. FA is thought to increase when this 
diffusion is highly ordered within intact WM. Our finding of a sub-threshold 
positive correlation between increased FA in the left superior fasiculus and a 
measure of global cognitive performance in healthy controls supports this 
interpretation of FA as an index of WM integrity.  The cingulum forms part of 
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the frontal-striatal network of WM, essential for higher-order executive 
functioning. Nevertheless we were unable to demonstrate a significant deficit 
in executive function in MA dependent individuals.  
Limitations 
The sample size of this study is small, though comparable to other DTI 
studies of MA use (Chung et al. 2007, Kim et al. 2009), and a larger sample 
may have provided sufficient power to yield positive findings. We were not 
able to include the WCST in our neuropsychological test battery, known to be 
associated with DTI abnormalities (Chung 2007, Kim 2009), due to time and 
resource constraints. MA users are expected to have comparatively lower 
mean scores for the neurocognitive tests, yet may still perform within the 
normed limits for their age and education (Hart et al. 2011).  The lack of group 
differences in test performance may reflect a selection bias within the healthy 
comparison group. The healthy control group was selected predominantly 
from family and friends accompanying the MA dependent user to their rehab 
visits and alcohol use was not excluded. Female healthy controls (n = 14) 
were mostly unemployed and had the highest scores on the AUDIT, which 
may, in turn, have contributed to impaired test scores. 
Due to the frequent co-morbidity of co-morbid cannabis use in this population, 
we elected not to exclude cannabis users for the MA+ group. Male MA users 
trended towards an increased co-morbid use of cannabis (p=0.06). Although 
not statistically significant, a larger sample size may have highlighted this 
potential difference between genders with implications for between group 
differences. Gonzalez et al. (2004) postulated a protective effect of cannabis 
on neurocognitive performance in MA abuse, yet were unable to demonstrate 
this. The authors concluded that comorbid cannabis use did not exacerbate 
the neurotoxic properties of MA, and recommended further studies of the 
potentially neuro-protective qualities of cannabis in the context of MA use 
(Gonzalez et al. 2004).  
Dosage is an important aspect of understanding the neurotoxic potential of 
MA. We attempted to determine an estimate of the dosage (based on self-
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report by MA dependent individuals), however, we feel that these estimates 
are highly inaccurate as MA in South Africa is frequently cut and sold with 
other inert substances and is therefore difficult to measure. Although the 
authors recommend a more accurate measurement of MA potency in future 
studies, we are aware that this is a near impossible task due to the variability 
of substance produced in informal MA labs. 
Conclusion 
The absence of neuropsychological or white matter deficits in this relatively 
young adults group of MA dependent individuals may suggest a 
neuroprotective aspect associated with younger age. There may indeed be a 
tipping-point, whereby neurotoxicity is reflected on cognitive measures and 
neuroimaging. The authors recommend further research examining the effects 
of age; co-morbid substance abuse and HIV co-infection using a matched-
control group. 
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Table 1: Participant demographic data and clinical characteristics 










Age, years, mean (SD) 28.55 (5.43) 25.05 (4.70) 29.59 (5.97) 26.66 (5.32) 
t = 2.91,(3), 
p = 0.41 
Years of formal education, 
mean (SD) 10.2 (2.49) 10.27 (2.2) 10.2 (2.49) 
10.21 
(1.31) 
t = 0.23,(3), 
p = 0.97 
Unemployed, % 10 (100%) 9 (82%) 2 (40%) 10 (71%) = 8.89, (4), p = 0.06 
Single, % 9 (90%) 9 (82%) 3 (60%) 7 (50%) = 8.27, (4), p = 0.08 
Living in family home, % 9 (90%) 9 (82%) 2(40%) 8 (57%) = 7.77, (4), p = 0.10 
Audit mean, (SD) 1.7, (2.1) 0.8, (1.7) 0.6, (1.3) 2.4,(3.1) t = 3.18, (3), p = 0.36 
Dudit mean, (SD) 21.4, (8.9) 19.3, (8.6) 0 (0) 0 (0) z =-1.10, (1), p = 0.27 
MA use characteristics 
Age, in years, of first use, 
mean, (SD) 20, (5.54) 19.11, (4.83) - - 
Z=-1.10, 
p = 0.71 
Weekly cost of MA, %: 
<R500 
R500 to R1000 










- - = 3.98, (3), p = 0.26 







- - = 1.55, (1), p = 0.21 
Daily dose in grams, 
mean, (SD) 2.17, (2.11) 1.51, (1.83) - - 
Z = -1.07, 
p = 0.28 
Duration of use, yrs, 
mean, (SD) 8.01, (4.13) 6.72, (3.12) - - 
Z = -0.53, 
p = 0.59 
Days abstinent, mean, 
(SD) 38.8, (23.0) 60.9, (38.9) - - 
Z = 1.09, 
p = 0.27 
Co-morbid cannabis use, 
% 80 40 - - 
= 3.33, (1), 
p = 0.06 
Note: MA = methamphetamine; SD  = standard deviation; AUDIT = Alcohol Use Disorders 
Identification Test; DUDIT = Drug Use Disorders Identification Test; IQR = interquartile range 
a degrees of freedom in parentheses 
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Table 2: Neuropsychological performance of MA users and healthy 
              comparison subjects 
Variable a MA + 
(n = 21) 
MA – 
(n = 19) 
Statistic Adjusted statistic b
Motor speed 
  GP Dominant 68.1 (7.87) 69.32 (8.49) 
  GP Non-dominant 71.86 (9.06) 71.26 (8.69) 
Motor speed Z 0.02 (0.89) -0.02 (0.87) t = -0.15 (37.78), 
p = 0.88 t = 1.30, p =    0.20 
Episodic memory 
  HVLT-R total 20.86 (4.08) 20.89 (4.25) 
  HVLT-R delay 7.29  (2) 6.47 (2.55) 
 Episodic memory Z 0.08 (0.87) -0.09 (1.01) t = -0.58 (35.75), 
p = 0.57 t = 0.64, p =    0.53 
Attention/working 
memory 
  Digit span 11.29 (3.3) 12.11 (2.81) 
Working memory Z -0.13 (1.0) 0.14 (0.92) 
t = 0.85 (37.9), p 
= .40 




  Colour trails I 51 (16.64) 43.26 (9.8) 
  Digit symbol 45.48 (11.49) 50.58 (12.78) 
  Stroop Color 
Naming 
45.71 (14.54) 38.16 (11.62) 
Info speed Z -0.12 (0.85) 0.14 0.49 t = 1.22 (32.51), p = 0.23 t = -1.07. p = 0.29 
Verbal fluency 
  COWAT – FAS 0.17 (0.99) -0.19 (0.79)
  Animal fluency 33.76 (7.83) 32.37 (7.15) 
Fluency Z 0.17 (0.99) -0.19 (0.79)
t = -1.25 (37.44), 
p = 0.22 t = 1.24, p =   0.22 
Executive function c
  Stroop Color and 
Word Test 
45.71 (14.54) 38.16 (11.62) 
  Colour trails 2 92.76 (26.05) 88.11 (18.61) 
  Hayling Test 6.4 (3.68) 7.47 (4.59) 
Executive function Z 0.03 (0.77) -0.02 (0.68)
t = -0.19 (36.80), 
p = 0.85 t = 0.13, p = 0.90 
Note: aAll scores represent raw scores, presented as means and standard deviations. Higher domain Z scores reflect 
better test performance. b Group comparisons after adjusting for the effects of gender and age within a linear 
regression model  c Data was missing for one MA + participant. 
MA + = Methamphetamine user; MA - = healthy comparison subject 
HVLT-R = Hopkins Verbal Learning Test – Revised; COWAT – Controlled Oral Word Association Test; GP – 
Grooved Pegboard 
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Table 3: Differences between MA+ and MA- groups on DTI outcomes for 
tracts of interest 








Genu CC 0.39 ±0.04 0.40 ±0.03 0,014 +-0,012 t = 1,21 p = 0,23 
Body CC 0.39 ±0.04 0.39 ±0.02 0,006 +-0,011 t = 0,48 p = 0,63 
R Cingulum 0.38 ±0.04 0.40 ±0.03 0,020 +-0,012 t = 1,61 p = 0,12 
L Cingulum 0.41 ±0.03 0.41 ±0.02 0,004 +-0,009 t = 0,49 p = 0,63 
R Uncinate fasciculus 0.32 ±0.05 0.33 ±0.04 0,006 +-0,015 t = 0,37 p = 0,71 
L Uncinate fasciculus 0.45 ±0.04 0.45 ±0.02 0,007 +-0,010 t = 0,66 p = 0,51 
R Ant corona radiata 0.49 ±0.04 0.49 ±0.03 0,009 +-0,012 t = 0,78 p = 0,44 
L Ant corona radiata 0.48 ±0.04 0.49 ±0.02 0,005 +-0,010 t = 0,53 p = 0,60 
R Sup long fasciculus 0.38 ±0.04 0.37 ±0.04 -0,009+-0,013 t = -0,73 p = 0,47 
L Sup long fasciculus 0.34 ±0.04 0.36 ±0.02 0,019 +-0,010 t = 1,96 p = 0,06* 
MD 
Genu CC 0.75 ±0.03 0.75 ±0.03 0,051 +-0,103 t = 0,49 p = 0,62 
Body CC 0.72 ±0.04 0.73 ±0.02 0,056 +-0,0965 t = 0,58 p = 0,56 
R Cingulum 0.82 ±0.03 0.82 ±0.03 -0,048 +-0,091 t = -0,53 p = 0,60 
L Cingulum 0.70 ±0.03 0.70 ±0.03 -0,057 +-0,082 t = -0,69 p = 0,49 
R Uncinate fasciculus 1.38 ±0.15 1.31 ±0.13 -0,759 +-0,425 t = -1,79 p = 0,08* 
L Uncinate fasciculus 0.68 ±0.03 0.68 ±0.03 -0,027 +-0,105 t = -0,26 p = 0,79 
R Ant corona radiata 0.93 ±0.08 0.94 ±0.06 0,031 +-0,238 t = 0,13 p = 0,89 
L Ant corona radiata 0.83 ±0.06 0.82 ±0.04 -0,058 +-0,157 t = -0,37 p = 0,71 
R Sup long fasciculus 0.81 ±0.08 0.83 ±0.09 0,368 +-0,268 t = 1,37 p = 0,18 
L Sup long fasciculus 1.48 ±0.14 1.43 ±0.13 -0,630 +-0,435 t = -1,45 p = 0,16 
Model coefficients extracted from multiple linear regression of DTI outcomes on group membership, 
adjusting for differences in gender and age. 
MD values multiplied by 1000 
*p<0.1, **p<0.05
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Table 4: DTI correlates of Global Neurocognitive Score 
Region of interest rho MA+ alpha  rho MA- alpha 
FA 
Genu CC -0.356 p = 0.12 -0.03 p = 0.92 
Body CC -0.30 p = 0.19 0.04 P = 0.88 
R Cingulum -0.14 p = 0.56 0.31 p = 0.20 
L Cingulum -0.26 p = 0.28 -0.08 p = 0.75 
R Uncinate fasciculus -0.17 p = 0.48 -0.14 p = 0.58 
L Uncinate fasciculus -0.48 p = 0.04 0.05 p = 0.85 
R Anterior Corona Radiata -0.15 p = 0.52 0.36 p = 0.13 
L Anterior Corona Radiata -0.24 p = 0.31 -0.04 p = 0.87 
R Superior longitudinal fasciculus -0.23 p = 0.33 0.20 p = 0.42 
L Superior longitudinal fasciculus -0.29 p = 0.21 0.05 p = 0.85 
MD 
Genu CC 0.32 p = 0.17 0.05 p = 0.83 
Body CC 0.29 p = 0.22 -0.12 p = 0.62 
R Cingulum 0.21 p = 0.38 -0.03 p = 0.91 
L Cingulum 0 p = 1 -0.07 p = 0.79 
R Uncinate fasciculus 0.09 p = 0.72 0.36 p = 0.13 
L Uncinate fasciculus -0.7 p = 0.78 0.03 p = 0.90 
R Anterior Corona Radiata 0.38 p = 0.10 -0.11 p = 0.66 
L Anterior Corona Radiata 0.26 p = 0.26 0.07 p = 0.78 
R Superior longitudinal fasciculus 0.14 p = 0.55 -0.45 p = 0.05 
L Superior longitudinal fasciculus 0.22 p = 0.35 0.01 p = 0.97 
MA+ = MA dependent 
Bonferroni corrected p = 0.00 
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Supplementary material 
Table S1: Mean DTI values in MA dependent individuals and healthy control subjects 





MD★ MA+ MD★  MA- MD: 
t value, 
p value 
Middle cerebellar peduncle 0.43 ±0.04 0.43 ±0.02 t = -0.75, p = 0.46 0.71 ±0.03 0.71 ±0.03 t = -0.08, p = 0.93 
Pontine crossing tract 0.47 ±0.04 0.47 ±0.02 t = -0.64, p =  0.54 0.69 ±0.02 0.68 ±0.02 t = 1.08, p = 0.29 
Genu CC 0.39 ±0.04 0.40 ±0.03 t = -1.12, p = 0.27 0.75 ±0.03 0.75 ±0.03 t = -0.23, p = 0.82 
Body CC 0.39 ±0.04 0.39 ±0.02 t = -0.29, p = 0.78 0.72 ±0.04 0.73 ±0.02 t = -0.41, p = 0.68 
Splenium CC 0.45 ±0.03 0.45 ±0.03 t = -0.04, p = 0.97 0.96 ±0.07 0.96 ±0.03 t = 0.08, p = 0.94 
Fornix 0.43 ±0.03 0.43 ±0.02 t = -0.36, p = 0.72 1.03 ±0.08 1.03 ±0.04 t = 0.09, p =  0.93 
R Corticospinal tract 0.56 ±0.04 0.56 ±0.02 t = -0.41, p = 0.69 0.75 ±0.03 0.74 ±0.02 t = 1.09, p =  0.28 
L Corticospinal tract 0.55 ±0.04 0.55 ±0.02 t = -0.52, p = 0.61 0.73 ±0.02 0.72 ±0.02 t = 0.63, p = 0.53 
R Medial lemniscus 0.47 ±0.04 0.47 ±0.03 t = -0.14, p = 0.89 0.66 ±0.04 0.66 ±0.03 t = 0.15, p = 0.88 
L Medial lemniscus 0.46 ±0.03 0.46 ±0.02 t = -0.60, p = 0.55 0.67 ±0.03 0.68 ±0.02 t = -0.74, p = 0.47 
R Inf cerebellar peduncle 0.54 ±0.03 0.54 ±0.02 t = 0.02, p = 0.99 0.69 ±0.03 0.69 ±0.02 t = 0.26, p = 0.79 
L Inf cerebellar peduncle 0.36 ±0.04 0.37 ±0.02 t = -1.03, p = 0.31 0.67 ±0.03 0.67 ±0.03 t= 0.36, p = 0.72 
R Sup cerebellar peduncle 0.54 ±0.03 0.54 ±0.01 t = -0.28, p = 0.78 0.70 ±0.02 0.70 ±0.02 t = -1.18, p = 0.25 
L Sup cerebellar peduncle 0.49 ±0.04 0.49 ±0.03 t = 0.22, p = 0.82 0.74 ±0.03 0.74 ±0.02 t = 0.39, p = 0.71 
R Cerebral peduncle 0.47 ±0.04 0.47 ±0.03 t = -0.65, p = 0.52 0.74 ±0.03 0.74 ±0.03 t = 0.06, p = 0.95 
L Cerebral peduncle 0.39 ±0.03 0.39 ±0.03 t = 0.08, p = 0.94 0.72 ±0.03 0.72 ±0.03 t = -0.74, p = 0.47 
R Ant limb of int capsule 0.39 ±0.03 0.39 ±0.02 t = 0.19, p = 0.84 0.72 ±0.03 0.73 ±0.03 t = -0.72, p = 0.48 
L Ant limb of int capsule 0.42 ±0.03 0.43 ±0.02 t = -0.89, p = 0.38 0.69 ±0.03 0.69 ±0.02 t = 0.28, p = 0.78 
R Post limb of int capsule 0.41 ±0.03 0.41 ±0.02 t = -0.25, p = 0.80 0.69 ±0.03 0.73 ±0.03 t = -1.11, p = 0.28 
L Post limb of int capsule 0.42 ±0.03 0.42 ±0.03 t = -0.79, p = 0.44 0.78 ±0.04 0.78 ±0.04 t = 0.14, p = 0.89 
R Retrolenticular int capsule 0.39 ±0.03 0.40 ±0.02 t = -0.72, p = 0.48 0.79 ±0.04 0.78 ±0.03 t = 0.32, p = 0.75 
L Retrolenticular int capsule 0.51 ±0.04 0.51 ±0.02 t = 0.25, p = 0.81 0.81 ±0.06 0.80 ±0.04 t = 1.09, p = 0.28 
R Ant corona radiata 0.49 ±0.04 0.49 ±0.03 t = -0.48, p = 0.63 0.93 ±0.08 0.94 ±0.06 t = -0.12, p = 0.90 
L Ant corona radiata 0.48 ±0.04 0.49 ±0.02 t = -0.45, p = 0.65 0.83 ±0.06 0.82 ±0.04 t = 0.28, p = 0.78 
R Sup corona radiata 0.46 ±0.03 0.45 ±0.03 t = 0.45, p = 0.65 0.83 ±0.04 0.82 ±0.03 t = 1.07, p = 0.29 
L Sup corona radiata 0.41 ±0.03 0.41 ±0.02 t = 0.12, p = 0.90 0.81 ±0.04 0.81 ±0.04 t = 0.70, p = 0.48 
R Post corona radiata 0.34 ±0.03 0.34 0.02 t = 0.01, p = 0.99 0.73 ±0.03 0.72 ±0.02 t = 0.09, p = 0.92 
L Post corona radiata 0.33 ±0.03 0.33 ±0.02 t = -0.23, p = 0.82 0.75 ±0.03 0.76 ±0.02 t = -1.44, p = 0.15 
R Post thalamic radiation 0.40 ±0.04 0.39 ±0.03 t = 0.57, p = 0.57 0.72 ±0.03 0.72 ±0.02 t = 0.73, p = 0.47 
L Post thalamic radiation 0.42 ±0.04 0.41 ±0.03 t = 0.22, p = 0.83 0.70 ±0.03 0.70 ±0.02 t = -0.17, p = 0.87 
R Sagittal stratum 0.29 ±0.05 0.29 ±0.04 t = -0.02, p = 0.98 0.81 ±0.04 0.81 ±0.05 t = -0.19, p = 0.84 
L Sagittal stratum 0.28 ±0.05 0.29 ±0.03 t = -0.31, p = 0.76 0.82 ±0.06 0.82 ±0.05 t = 0.47, p = 0.64 
R Ext capsule 0.38 ±0.04 0.38 ±0.04 t = -0.44, p = 0.66 0.91 ±0.03 0.89 ±0.03 t = 2.33, p = 0.02* 
L Ext capsule 0.50 ±0.07 0.53 ±0.03 t = -1.44, p = 0.16 0.88 ±0.07 0.86 ±0.03 t = 1.30, p = 0.20 
R Cingulum 0.38 ±0.04 0.40 ±0.03 t = -1.49, p = 0.14 0.82 ±0.03 0.82 ±0.03 t = 0.29, p = 0.77 
L Cingulum 0.41 ±0.03 0.41 ±0.02 t = -0.21, p = 0.84 0.70 ±0.03 0.70 ±0.03 t = 0.25, p = 0.80 
R Cingulum hippocampus 0.38 ±0.02 0.39 ±0.02 t = -0.85, p = 0.40 0.71 ±0.02 0.72 ±0.02 t = -0.86, p = 0.39 
L Cingulum hippocampus 0.40 ±0.05 0.41 ±0.03 t = -0.72, p = 0.47 0.66 ±0.03 0.65 ±0.02 t = 0.61, p = 0.54 
R Fornix stria terminalis 0.38 ±0.05 0.38 ±0.03 t = -0.15, p = 0.88 0.67 ±0.04 0.68 ±0.03 t = -0.29, p = 0.78 
L Fornix stria terminalis 0.42 ±0.04 0.42 ±0.03 t = 0.19, p = 0.85 0.72 ±0.06 0.70 ±0.05 t = 0.83, p = 0.41 
R Sup long fasciculus 0.38 ±0.04 0.37 ±0.04 t = 0.56, p = 0.58 0.81 ±0.08 0.83 ±0.09 t = -0.91, p = 0.37 
L Sup long fasciculus 0.34 ±0.04 0.36 ±0.02 t = -1.37, p = 0.18 1.48 ±0.14 1.43 ±0.13 t = 1.18, p = 0.25 
R Sup fronto occ fasciculus 0.27 ±0.03 0.27 ±0.02 t = -0.69, p = 0.49 1.75 ±0.14 1.74 ±0.12 t = 0.29, p = 0.77 
L Sup fronto occ fasciculus 0.63 ±0.04 0.64 ±0.02 t = -0.81, p  = 0.43 0.77 ±0.03 0.77 ±0.02 t = 0.87, p = 0.39 
R Uncinate fasciculus 0.32 ±0.05 0.33 ±0.04 t = -0.22, p = 0.82 1.38 ±0.15 1.31 ±0.13 t = 1.52, p = 0.14 
L Uncinate fasciculus 0.45 ±0.04 0.45 ±0.02 t = -0.29, p = 0.77 0.68 ±0.03 0.68 ±0.03 t = 0.67, p = 0.49 
R Tapetum 0.46 ±0.04 0.46 ±0.02 t = -0.15, p = 0.88 0.66 ±0.03 0.65 ±0.02 t = 0.59, p = 0.56 
L Tapetum 0.47 ±0.04 0.48 ±0.03 t = -0.85, p = 0.39 0.70 ±0.02 0.68 ±0.03 t = 1.76, p = 0.09** 
★MD value has been multiplied by 1000
*p<0.1, **p<0.05
MA + = Methamphetamine user; MA - = healthy comparison subject
FA = fractional anisotropy; MD = mean diffusion; CC = corpus callosum; WM = white matter; Sup = superior; Inf =
inferior; Ant = anterior; Post = posterior; Int = internal; Ext = external; long = longitudinal; Occ = occipital
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Middle cerebellar peduncle 0,011	 0,009	 t	=	1,24	 p	=	0,22	 -0,001 0,001	 t	=	-1,26	 p	=	0,22	 0,018	 0,010	 t	=	1,87	 p	=	0,07*	 1,53	
Pontine crossing tract 0,012	 0,010	 t	=	1,17	 p	=	0,25	 -0,001 0,001	 t	=	-1,14	 p	=	0,26	 0,022	 0,011	 t	=	2,09	 p	=	0,04**	 1,69	
Genu CC 0,014	 0,012	 t	=	1,21	 p	=	0,23	 0,000	 0,001	 t	=	-0,38	 p	=	0,70	 0,007	 0,013	 t	=	0,59	 p	=	0,56	 0,53	
Body CC  0,006	 0,011	 t	=	0,48	 p	=	0,63	 0,000	 0,001	 t	=	-0,06	 p	=	0,95	 0,011	 0,012	 t	=	0,92	 p	=	0,36	 0,32	
Splenium CC 0,002	 0,009	 t	=	0,24	 p	=	0,81	 0,001	 0,001	 t	=	0,83	 p	=	0,41	 0,011	 0,010	 t	=	1,14	 p	=	0,26	 0,94	
Fornix 0,004	 0,009	 t	=	0,50	 p	=	0,62	 0,001	 0,001	 t	=	1,10	 p	=	0,28	 0,010	 0,009	 t	=	1,03	 p	=	0,31	 1,11	
R Corticospinal tract 0,007	 0,011	 t	=	0,66	 p	=	0,51	 -0,001 0,001	 t	=	-1,11	 p	=	0,27	 0,011	 0,012	 t	=	0,90	 p	=	0,37	 0,58	
L Corticospinal tract 0,010	 0,010	 t	=	0,95	 p	=	0,35	 -0,001 0,001	 t	=	-1,29	 p	=	0,20	 0,018	 0,011	 t	=	1,60	 p	=	0,12	 1,19	
R Medial lemniscus 0,006	 0,011	 t	=	0,51	 p	=	0,61	 0,000	 0,001	 t	=	-0,41	 p	=	0,68	 0,018	 0,012	 t	=	1,53	 p	=	0,14	 0,78	
L Medial lemniscus 0,009	 0,009	 t	=	1,04	 p	=	0,30	 -0,001 0,001	 t	=	-0,61	 p	=	0,55	 0,018	 0,010	 t	=	1,87	 p	=	0,07*	 1,29	
R Inf cerebellar peduncle 0,002	 0,008	 t	=	0,27	 p	=	0,79	 -0,001 0,001	 t	=	-0,83	 p	=	0,41	 0,009	 0,009	 t	=	1,02	 p	=	0,32	 0,45	
L Inf cerebellar peduncle 0,012	 0,011	 t	=	1,05	 p	=	0,30	 -0,001 0,001	 t	=	-0,65	 p	=	0,52	 0,003	 0,012	 t	=	0,24	 p	=	0,81	 0,46	
R Sup cerebellar peduncle 0,005	 0,007	 t	=	0,71	 p	=	0,48	 -0,001 0,001	 t	=	-0,80	 p	=	0,43	 0,013	 0,008	 t	=	1,70	 p	=	0,10	 1,02	
L Sup cerebellar peduncle -0,002 0,012	 t	=	-0,14	 p	=	0,89	 -0,001 0,001	 t	=	-1,29	 p	=	0,21	 -0,001 0,013	 t	=	-0,06	 p	=	0,95	 0,64	
R Cerebral peduncle 0,010	 0,012	 t	=	0,84	 p	=	0,41	 -0,001 0,001	 t	=	-0,48	 p	=	0,63	 0,010	 0,012	 t	=	0,81	 p	=	0,42	 0,38	
L Cerebral peduncle 0,005	 0,010	 t	=	0,49	 p	=	0,63	 -0,001 0,001	 t	=	-1,25	 p	=	0,22	 0,022	 0,010	 t	=	2,10	 p	=	0,04**	 1,62	
R Ant limb of int capsule 0,003	 0,009	 t	=	0,36	 p	=	0,72	 -0,002 0,001	 t	=	-2,11	 p	=	0,04**	 0,017	 0,009	 t	=	1,83	 p	=	0,08*	 2,03	
L Ant limb of int capsule 0,009	 0,008	 t	=	1,11	 p	=	0,27	 -0,001 0,001	 t	=	-1,04	 p	=	0,30	 0,007	 0,009	 t	=	0,87	 p	=	0,39	 0,73	
R Post limb of int capsule 0,005	 0,008	 t	=	0,68	 p	=	0,50	 -0,001 0,001	 t	=	-1,53	 p	=	0,13	 0,012	 0,008	 t	=	1,47	 p	=	0,15	 1,18	
L Post limb of int capsule 0,011	 0,010	 t	=	1,18	 p	=	0,25	 -0,002 0,001	 t	=	-1,76	 p	=	0,09*	 0,013	 0,010	 t	=	1,26	 p	=	0,22	 1,44	
R Retrolenticular int capsule 0,010	 0,009	 t	=	1,09	 p	=	0,28	 -0,002 0,001	 t	=	-2,14	 p	=	0,04**	 0,009	 0,009	 t	=	0,99	 p	=	0,33	 1,75	
L Retrolenticular int capsule -0,002 0,011	 t	=	-0,22	 p	=	0,82	 -0,001 0,001	 t	=	-0,74	 p	=	0,47	 -0,002 0,012	 t	=	-0,20	 p	=	0,84	 0,26	
R Ant corona radiata 0,009	 0,012	 t	=	0,78	 p	=	0,44	 -0,001 0,001	 t	=	-1,05	 p	=	0,30	 0,013	 0,012	 t	=	1,09	 p	=	0,28	 0,66	
L Ant corona radiata 0,005	 0,010	 t	=	0,53	 p	=	0,60	 -0,001 0,001	 t	=	-1,35	 p	=	0,19	 0,000	 0,011	 t	=	0,05	 p	=	0,96	 0,71	
R Sup corona radiata -0,003 0,011	 t	=	-0,31	 p	=	0,76	 -0,001 0,001	 t	=	-0,89	 p	=	0,38	 0,003	 0,011	 t	=	0,26	 p	=	0,79	 0,33	
L Sup corona radiata 0,002	 0,009	 t	=	0,21	 p	=	0,84	 -0,001 0,001	 t	=	-0,82	 p	=	0,42	 0,011	 0,009	 t	=	1,17	 p	=	0,25	 0,54	
R Post corona radiata 0,004	 0,007	 t	=	0,56	 p	=	0,58	 -0,001 0,001	 t	=	-1,23	 p	=	0,23	 0,016	 0,008	 t	=	2,13	 p	=	0,04**	 1,64	
L Post corona radiata 0,004	 0,008	 t	=	0,59	 p	=	0,56	 -0,001 0,001	 t	=	-0,76	 p	=	0,46	 0,011	 0,008	 t	=	1,41	 p	=	0,17	 0,72	
R Post thalamic radiation -0,002 0,011	 t	=	-0,17	 p	=	0,87	 0,000	 0,001	 t	=	0,12	 p	=	0,90	 0,020	 0,012	 t	=	1,72	 p	=	0,09*	 1,24	
L Post thalamic radiation 0,002	 0,011	 t	=	0,19	 p	=	0,85	 0,000	 0,001	 t	=	-0,07	 p	=	0,94	 0,021	 0,012	 t	=	1,74	 p	=	0,09*	 1,09	
R Sagittal stratum -0,002 0,016	 t	=	-0,16	 p	=	0,88	 0,000	 0,002	 t	=	0,27	 p	=	0,79	 -0,012 0,017	 t	=	-0,69	 p	=	0,49	 0,16	
L Sagittal stratum 0,008	 0,015	 t	=	0,54	 p	=	0,59	 -0,001 0,001	 t	=	-0,65	 p	=	0,52	 0,014	 0,016	 t	=	0,91	 p	=	0,37	 0,36	
R Ext capsule 0,005	 0,013	 t	=	0,38	 p	=	0,70	 -0,001 0,001	 t	=	-0,72	 p	=	0,48	 -0,005 0,014	 t	=	-0,35	 p	=	0,73	 0,35	
L Ext capsule 0,028	 0,017	 t	=	1,69	 p	=	0,10	 -0,002 0,002	 t	=	-1,25	 p	=	0,22	 0,020	 0,018	 t	=	1,10	 p	=	0,28	 1,37	
R Cingulum 0,020	 0,012	 t	=	1,61	 p	=	0,12	 -0,001 0,001	 t	=	-0,48	 p	=	0,63	 0,011	 0,013	 t	=	0,80	 p	=	0,43	 0,93	
L Cingulum 0,004	 0,009	 t	=	0,49	 p	=	0,63	 -0,001 0,001	 t	=	-0,83	 p	=	0,41	 0,010	 0,009	 t	=	1,02	 p	=	0,31	 0,47	
R Cingulum hippocampus 0,008	 0,007	 t	=	1,09	 p	=	0,28	 0,000	 0,001	 t	=	-0,68	 p	=	0,50	 0,008	 0,007	 t	=	1,01	 p	=	0,32	 0,63	
L Cingulum hippocampus 0,014	 0,013	 t	=	1,10	 p	=	0,28	 -0,001 0,001	 t	=	-0,82	 p	=	0,42	 0,022	 0,014	 t	=	1,56	 p	=	0,13	 1,03	
R Fornix stria terminalis 0,006	 0,013	 t	=	0,45	 p	=	0,65	 -0,001 0,001	 t	=	-0,57	 p	=	0,57	 0,016	 0,014	 t	=	1,17	 p	=	0,25	 0,48	
L Fornix stria terminalis 0,000	 0,011	 t	=	0,02	 p	=	0,98	 0,001	 0,001	 t	=	0,52	 p	=	0,60	 0,012	 0,012	 t	=	1,05	 p	=	0,30	 0,63	
R Sup long fasciculus -0,009 0,013	 t	=	-0,73	 p	=	0,47	 0,000	 0,001	 t	=	-0,24	 p	=	0,81	 -0,013 0,014	 t	=	-0,94	 p	=	0,36	 0,49	
L Sup long fasciculus 0,019	 0,010	 t	=	1,96	 p	=	0,06*	 -0,002 0,001	 t	=	-1,94	 p	=	0,06*	 0,021	 0,010	 t	=	2,07	 p	=	0,05*	 2,72	
R Sup fronto occ fasciculus 0,007	 0,007	 t	=	0,97	 p	=	0,34	 0,000	 0,001	 t	=	-0,41	 p	=	0,68	 0,010	 0,008	 t	=	1,25	 p	=	0,22	 0,68	
L Sup fronto occ fasciculus 0,011	 0,011	 t	=	1,08	 p	=	0,29	 -0,001 0,001	 t	=	-1,10	 p	=	0,28	 0,012	 0,011	 t	=	1,09	 p	=	0,29	 0,82	
43	
R Uncinate fasciculus 0,006	 0,015	 t	=	0,37	 p	=	0,71	 -0,003 0,001	 t	=	-2,10	 p	=	0,04**	 0,001	 0,016	 t	=	0,03	 p	=	0,97	 1,61	
L Uncinate fasciculus 0,007	 0,010	 t	=	0,66	 p	=	0,51	 -0,001 0,001	 t	=	-1,01	 p	=	0,32	 0,015	 0,011	 t	=	1,38	 p	=	0,18	 0,79	
R Tapetum 0,006	 0,011	 t	=	0,54	 p	=	0,59	 -0,001 0,001	 t	=	-0,54	 p	=	0,59	 0,018	 0,011	 t	=	1,55	 p	=	0,13	 0,82	
L Tapetum 0,013	 0,011	 t	=	1,26	 p	=	0,22	 -0,001 0,001	 t	=	-0,68	 p	=	0,50	 0,020	 0,011	 t	=	1,70	 p	=	0,10	 1,22	
*p<0.1, **p<0.05 
MA + = Methamphetamine user; MA - = healthy comparison subject; ROI = region of interest 
FA = fractional anisotropy; MD = mean diffusion; CC = corpus callosum; WM = white matter; Sup = superior; Inf = inferior; Ant = anterior; Post = posterior; Int = internal; Ext = external; long = longitudinal; Occ = occipital 
44	


























Middle cerebellar peduncle 0,0206	 0,0994	 t	=	0,21	 p	=	0,84	 -0,0107 0,0096	 t	=	-1,12	 p	=	0,27	 0,0232	 0,1060	 t	=	0,22	 p	=	0,83	 0,42	
Pontine crossing tract -0,0642 0,0625	 t	=	-1,03	 p	=	0,31	 -0,0064 0,0060	 t	=	-1,06	 p	=	0,29	 -0,0202 0,0668	 t	=	-0,30	 0,76	 0,89	
Genu CC 0,0507	 0,1030	 t	=	0,49	 p	=	0,62	 -0,0224 0,0099	 t	=	-2,25	 p	=	0,03**	 0,0535	 0,1100	 t	=	0,49	 0,63	 1,72	
Body CC  0,0556	 0,0955	 t	=	0,58	 p	=	0,56	 -0,0214 0,0092	 t	=	-2,31	 p	=	0,03**	 0,0048	 0,1020	 t	=	0,05	 0,96	 1,99	
Splenium CC 0,0246	 0,1730	 t	=	0,14	 p	=	0,89	 -0,0258 0,0167	 t	=	-1,55	 p	=	0,13	 0,0857	 0,1850	 t	=	0,46	 0,65	 0,79	
Fornix 0,0517	 0,2070	 t	=	0,25	 p	=	0,80	 -0,0342 0,0200	 t	=	-1,71	 p	=	0,09*	 0,2090	 0,2220	 t	=	0,94	 0,35	 1,04	
R Corticospinal tract -0,0847 0,0849	 t	=	-0,99	 p	=	0,33	 -0,0050 0,0082	 t	=	-0,61	 p	=	0,55	 -0,0062 0,0908	 t	=	-0,07	 0,95	 0,52	
L Corticospinal tract -0,0636 0,0734	 t	=	-0,87	 p	=	0,39	 -0,0044 0,0071	 t	=	-0,61	 p	=	0,54	 -0,1030 0,0785	 t	=	-1,31	 0,19	 1,07	
R Medial lemniscus -0,0829 0,0995	 t	=	-0,83	 p	=	0,41	 0,0022	 0,0096	 t	=	0,23	 p	=	0,82	 -0,3110 0,1060	 t	=	-2,92	 0,01**	 2,99	
L Medial lemniscus 0,0477	 0,0847	 t	=	0,56	 p	=	0,58	 -0,0069 0,0082	 t	=	-0,84	 p	=	0,40	 -0,0810 0,0906	 t	=	-0,89	 0,38	 0,89	
R Inf cerebellar peduncle -0,0408 0,0861	 t	=	-0,47	 p	=	0,64	 0,0085	 0,0083	 t	=	1,01	 p	=	0,32	 -0,0636 0,0921	 t	=	-0,69	 0,49	 0,42	
L Inf cerebellar peduncle -0,0268 0,0894	 t	=	-0,30	 p	=	0,77	 -0,0095 0,0086	 t	=	-1,09	 p	=	0,28	 -0,0127 0,0956	 t	=	-0,13	 0,89	 0,52	
R Sup cerebellar peduncle 0,0221	 0,0445	 t	=	0,49	 p	=	0,62	 -0,0010 0,0043	 t	=	-0,23	 p	=	0,82	 -0,1790 0,0476	 t	=	-3,77	 0,001**	 6,03	
L Sup cerebellar peduncle -0,0621 0,0888	 t	=	-0,69	 p	=	0,49	 0,0192	 0,0086	 t	=	2,24	 p	=	0,03**	 -0,0710 0,0949	 t	=	-0,75	 0,46	 1,72	
R Cerebral peduncle -0,0424 0,0967	 t	=	-0,44	 p	=	0,66	 0,0039	 0,0094	 t	=	0,42	 p	=	0,68	 -0,1600 0,1030	 t	=	-1,54	 0,13	 0,79	
L Cerebral peduncle -0,0013 0,0928	 t	=	-0,01	 p	=	0,99	 0,0117	 0,0089	 t	=	1,30	 p	=	0,20	 -0,3060 0,0992	 t	=	-3,08	 0,003**	 3,44	
R Ant limb of int capsule 0,0349	 0,0919	 t	=	0,38	 p	=	0,71	 0,0085	 0,0089	 t	=	0,96	 p	=	0,34	 -0,1050 0,0983	 t	=	-1,06	 0,29	 0,70	
L Ant limb of int capsule -0,0709 0,0873	 t	=	-0,81	 p	=	0,42	 0,0243	 0,0084	 t	=	2,88	 p	=	0,01**	 -0,1340 0,0934	 t	=	-1,43	 0,16	 2,92	
R Post limb of int capsule 0,0285	 0,0658	 t	=	0,43	 p	=	0,67	 0,0193	 0,0064	 t	=	3,03	 p	=	0,004**	 -0,1820 0,0703	 t	=	-2,59	 0,01**	 4,66	
L Post limb of int capsule -0,0662 0,1110	 t	=	-0,59	 p	=	0,56	 0,0338	 0,0108	 t	=	3,14	 p	=	0,003**	 -0,1190 0,1190	 t	=	-0,99	 0,33	 3,29	
R Retrolenticular int capsule -0,0556 0,1140	 t	=	-0,49	 p	=	0,63	 0,0253	 0,0110	 t	=	2,30	 p	=	0,02**	 -0,0062 0,1220	 t	=	-0,05	 0,96	 1,95	
L Retrolenticular int capsule -0,1610 0,1500	 t	=	-1,08	 p	=	0,29	 0,0285	 0,0145	 t	=	1,97	 p	=	0,06*	 0,1040	 0,1610	 t	=	0,65	 0,52	 2,26	
R Ant corona radiata 0,0306	 0,2380	 t	=	0,13	 p	=	0,89	 0,0147	 0,0230	 t	=	0,64	 p	=	0,53	 0,0627	 0,2540	 t	=	0,25	 0,81	 0,21	
L Ant corona radiata -0,0584 0,1570	 t	=	-0,37	 p	=	0,71	 0,0313	 0,0152	 t	=	2,06	 p	=	0,05*	 0,0300	 0,1680	 t	=	0,18	 0,86	 1,67	
R Sup corona radiata -0,1630 0,1120	 t	=	-1,46	 p	=	0,15	 0,0198	 0,0108	 t	=	1,83	 p	=	0,08*	 -0,1490 0,1200	 t	=	-1,25	 0,22	 1,69	
L Sup corona radiata -0,1170 0,1180	 t	=	-0,99	 p	=	0,32	 0,0148	 0,0114	 t	=	1,30	 p	=	0,20	 -0,1260 0,1260	 t	=	-0,10	 0,32	 0,87	
R Post corona radiata -0,0610 0,0853	 t	=	-0,71	 p	=	0,48	 0,0131	 0,0083	 t	=	1,59	 p	=	0,12	 -0,2040 0,0912	 t	=	-2,23	 0,03**	 1,98	
L Post corona radiata 0,0885	 0,0835	 t	=	1,06	 p	=	0,29	 0,0064	 0,0081	 t	=	0,79	 p	=	0,43	 -0,0988 0,0893	 t	=	-1,11	 0,28	 1,15	
R Post thalamic radiation -0,0933 0,0880	 t	=	-1,06	 p	=	0,29	 0,0080	 0,0085	 t	=	0,94	 p	=	0,36	 -0,1260 0,0941	 t	=	-1,34	 0,19	 0,88	
L Post thalamic radiation -0,0061 0,0771	 t	=	-0,08	 p	=	0,94	 0,0080	 0,0075	 t	=	1,07	 p	=	0,29	 -0,0586 0,0824	 t	=	-0,71	 0,48	 0,45	
R Sagittal stratum 0,0927	 0,1430	 t	=	0,65	 p	=	0,52	 -0,0093 0,0138	 t	=	-0,67	 p	=	0,51	 0,2720	 0,1530	 t	=	1,78	 0,08*	 1,07	
L Sagittal stratum -0,0733 0,1760	 t	=	-0,42	 p	=	0,68	 -0,0010 0,0171	 t	=	-0,05	 p	=	0,96	 0,0151	 0,1890	 t	=	0,08	 0,94	 0,07	
R Ext capsule -0,2620 0,1120	 t	=	-2,33	 p	=	0,03**	 0,0116	 0,0108	 t	=	1,07	 p	=	0,29	 -0,0192 0,1200	 t	=	-0,16	 0,87	 2,15	
L Ext capsule -0,2870 0,1760	 t	=	-1,63	 p	=	0,11	 0,0401	 0,0170	 t	=	2,35	 p	=	0,02**	 -0,1560 0,1890	 t	=	-0,83	 0,41	 2,43	
R Cingulum -0,0478 0,0906	 t	=	-0,53	 p	=	0,60	 0,0067	 0,0088	 t	=	0,76	 p	=	0,45	 -0,0815 0,0969	 t	=	-0,84	 0,41	 0,36	
L Cingulum -0,0571 0,0817	 t	=	-0,69	 p	=	0,49	 0,0200	 0,0079	 t	=	2,53	 p	=	0,02**	 -0,1020 0,0873	 t	=	-1,16	 0,25	 2,22	
R Cingulum hippocampus 0,0394	 0,0663	 t	=	0,59	 p	=	0,56	 0,0111	 0,0064	 t	=	1,74	 p	=	0,09*	 -0,0454 0,0709	 t	=	-0,64	 0,53	 1,27	
L Cingulum hippocampus -0,0860 0,0984	 t	=	-0,87	 p	=	0,39	 0,0079	 0,0095	 t	=	0,84	 p	=	0,41	 -0,1100 0,1050	 t	=	-1,04	 0,30	 0,58	
R Fornix stria terminalis -0,0160 0,1200	 t	=	-0,13	 p	=	0,89	 0,0133	 0,0116	 t	=	1,15	 p	=	0,26	 -0,1850 0,1280	 t	=	-1,45	 0,16	 0,912	
L Fornix stria terminalis -0,2050 0,1710	 t	=	-1,20	 p	=	0,24	 -0,0083 0,0165	 t	=	-0,50	 p	=	0,62	 -0,3370 0,1830	 t	=	-1,84	 0,07*	 1,77	
R Sup long fasciculus 0,3680	 0,2680	 t	=	1,37	 p	=	0,18	 -0,0169 0,0259	 t	=	-0,65	 p	=	0,52	 0,5410	 0,2870	 t	=	1,89	 0,07*	 1,47	
L Sup long fasciculus -0,6300 0,4350	 t	=	-1,45	 p	=	0,16	 0,0723	 0,0420	 t	=	1,72	 p	=	0,09	 -0,3690 0,4650	 t	=	-0,79	 0,43	 1,49	
R Sup fronto occ fasciculus -0,2220 0,4400	 t	=	-0,50	 p	=	0,63	 0,0189	 0,0425	 t	=	0,44	 p	=	0,66	 -0,4010 0,4700	 t	=	-0,85	 0,39	 0,28	
45	
L Sup fronto occ fasciculus -0,0984 0,0959	 t	=	-1,03	 p	=	0,31	 0,0182	 0,0093	 t	=	1,96	 p	=	0,06*	 -0,0183 0,1030	 t	=	-0,18	 0,86	 1,60	
R Uncinate fasciculus -0,7590 0,4250	 t	=	-1,79	 p	=	0,08*	 0,1080	 0,0410	 t	=	2,64	 p	=	0,01*	 -0,1060 0,4540	 t	=	-0,23	 0,82	 3,29	
L Uncinate fasciculus -0,0270 0,1050	 t	=	-0,26	 p	=	0,79	 -0,0105 0,0101	 t	=	-1,04	 p	=	0,31	 0,1640	 0,1120	 t	=	1,47	 0,15	 1,01	
R Tapetum -0,0222 0,0887	 t	=	-0,25	 p	=	0,80	 -0,0034 0,0086	 t	=	-0,41	 p	=	0,69	 0,1200	 0,0948	 t	=	1,26	 0,21	 0,65	
L Tapetum -0,1640 0,0857	 t	=	-1,91	 p	=	0,06*	 0,0001	 0,0083	 t	=	0,01	 p	=	0,99	 -0,0886 0,0917	 t	=	-0,97	 0,34	 1,36	
*p<0.1, **p<0.05 
MA + = Methamphetamine user; MA - = healthy comparison subject; ROI = region of interest
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UNIVERSITY OF CAPE TOWN
Faculty of Flealth Sciences
Human Research Ethics Committee
Room E52-24 Old Main Building
Groote Schuur Hospital
Observatory 7925






Psychiatry & Mental Health
J-Block, GSH
Dear A/Prof Joska
PROJECT TITLE: WHITE MATTER CORRELATES OF NEUROPSYCHOLOGICAL FUNCTION IN
YOUNG, METHAMPHETAMINE DEPENDENT INDIVIDUALS - A DIFFUSION TENSOR IMAGING
STUDY - SUB-STUDY LTNKED TO 236l2OtO (MPHIL CANDTDATE - DR C FREEMAN)
Thank you for subJnitting your sub-study to the Faculty of Health Sciences Human Research Ethics
Committee for review.
It is a pleasure to inform you that the HREC has formally approved the above-mentioned study.
Approva! is granted for one year until the 30th August 2015.
Please submit a progress form, using the standardised Annual Report Form if the study continues
beyond the approval period, Please submit a Standard Closure form if the study is completed within
the approval period.
(Forms can be found on our website: www.health.uct,ac.zalfhs/research/humanethics/forms)
We acknowledge that the MPHIL student, Dr Carla Patricia Freeman will also be involved in
this study.
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal
investigator.
Please quote the HREC reference no in all your correspondence.
Yours sincerely
op T.A*qX>" PRoFESSoR M BLoCKMAN
ru ernrcs
Federal Wide Assurance Number: FWA00001637.






What does my brain look like?
Matrix clinic, Cape Town.
28th June 2011
Dr. Carla Freeman 
Magnetic Resonance Image
MRI
How does MRI work?
• “The MAGNET”
• A powerful magnetic field is created in the 
bore
• Atoms are lined up
• Photographic “slices” of the brain can be seen
• Taken a step further, these images can be 
taken while performing a task
MRI and Safety
• No radiation
• Body returns to 
normal
• No long term 
damage
• Caution with 
metal objects





Not all brains are equal…
A quiz…




Methamphetamine and the brain… How does tik affect the body?
“Meth mouth” Time to reversal of the damage?
• Up to one year to reverse some effects
• The longer in a structured rehab, the better
the outcome
• Longer use had worse outcomes




Le: Freeman: Confirmation of Approval of Study Proposal - Carla Freeman https://pod5 l047.outlook.com/owa/projection.asp;
Re: Freeman: Confirmation of Approval of Study Proposal
John Joska <john.joska@uct.ac.za >
Mon 2015-01-26 05:04 PM
Inbox
To:Carla Freeman <FRMCAR002@myuct.ac.za> ;
The whip is ever on your back... !
From: Vuyi Mgoqi <vuvi.mgoqi(auct.ac.za>
Date: Monday 26January 2015 at 5:02 PM
To: Carla Freeman <tRMCAR002@mvuct.ac.za>
Cc: Jackie Cogill <jgg[!g.ggg!l]tr!gg3g,g>, John Joska <jgh&i"g!A@gS!A.g-Zg.>
Subject: Freeman: Confirmation of Approval of Study Proposal
Dear Dr Freeman
Candidature Approval (FRMCAR002)
Degree MPhil in Neuropsvchiatrv
Title White matter correlates of neuropsychological function in young
methamphetamine dependent individuals - a diffusion tensor imaging
studv
Department Psvchiatrv and Mental Health
Supervisor A/ProfJ Joska
Ethics Approval 635t2014
I am pleased to advise that the Chair of the Dissertations/Doctoral & Masters Committee has approved your candidature for the


















Tel: +27 21 404 5222 
Fax: +27 21 448 8158 
Email:  
Dr Hetta Gouse 
hetta.gouse@uct.ac.za  






















MATRIX PARTICIPANT INFORMATION LEAFLET AND 















to	 see	 how	well	 you	 can	 think,	 remember	 and	 do	 certain	 things.	 It	 will	 take	 about	 3	
hours.	This	will	be	 followed	by	a	medical	examination	performed	by	a	medical	doctor.	
Voluntary	pre	and	post-test	counselling	will	accompany	a	blood	test	to	confirm	your	HIV	
status.	 	 These	 results	will	 remain	 strictly	 confidential.	 	 Two	 additional	 tubes	 of	 blood	
will	 be	 taken	 for	 genetic	 testing.	 This	 blood	 will	 NOT	 be	 used	 to	 diagnose	 genetic	
illnesses.	 	It	will	only	be	used	to	further	understand	how	drugs	like	methamphetamine	































These	are	 the	main	risks.	You	should	 feel	 free	 to	mention	your	 feelings	or	concerns	 to	
any	member	of	the	study	team.	








other	 information	 to	 be	made	 available	 to	 the	Matrix	 clinic	 staff	 please	 indicate	 it	 by	
ticking	the	box	below	We	would	like	to	contact	you	in	six	months	for	a	follow	up	study.	
o DO	NOT	MAKE	MY	INFORMATION	AVAILABLE	TO	MATRIX	CLINIC	STAFF.
This study has been approved by the Human Research Ethics Committee 
(HREC)  of the Faculty of Health Sciences of the University of Cape Town and 
will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council (MRC) Ethical Guidelines for Research. 
For any queries regarding your rights as a participant, please contact the 
investigator, Dr Hetta Gouse (021 404 5224), Dr John Joska (021 404-2154) or 





 .....................................................................  ..................................................................  
Signature of participant Signature of witness 
Investigator/nurse/counsellor:	 “I	 have	 explained	 this	 study	 to	 the	 patient	 in	 a	way	
that	they	understand	and	allowed	them	to	ask	questions	
I	(name)	……………………………………………..………	declare	that:	
 .....................................................................  ..................................................................  
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